PMID- 38315411
OWN - NLM
STAT- Publisher
LR  - 20240205
IS  - 1573-2606 (Electronic)
IS  - 1389-9155 (Linking)
DP  - 2024 Feb 5
TI  - Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes 
      : Expert document.
LID - 10.1007/s11154-023-09871-9 [doi]
AB  - OBJECTIVES: To propose the grounds for "diabetic sarcopenia" as a new comorbidity 
      of diabetes, and to establish a muscle screening algorithm proposal to facilitate 
      its diagnosis and staging in clinical practice. METHOD: A qualitative expert 
      opinion study was carried out using the nominal technique. A literature search 
      was performed with the terms "screening" or "diagnostic criteria" and "muscle 
      loss" or "sarcopenia" and "diabetes" that was sent to a multidisciplinary group 
      of 7 experts who, in a face-to-face meeting, discussed various aspects of the 
      screening algorithm. RESULTS: The hallmark of diabetic sarcopenia (DS) is muscle 
      mass atrophy characteristic of people with diabetes mellitus (DM) in contrast to 
      the histological and physiological normality of muscle mass. The target 
      population to be screened was defined as patients with DM with a SARC-F 
      questionnaire > 4, glycosylated haemoglobin (HbA1C) >/= 8.0%, more than 5 years 
      since onset of DM, taking sulfonylureas, glinides and sodium/glucose 
      cotransporter inhibitors (SGLT2), as well as presence of chronic complications of 
      diabetes or clinical suspicion of sarcopenia. Diagnosis was based on the presence 
      of criteria of low muscle strength (probable sarcopenia) and low muscle mass 
      (confirmed sarcopenia) using methods available in any clinical consultation room, 
      such as dynamometry, the chair stand test, and Body Mass Index (BMI)-adjusted 
      calf circumference. DS was classified into 4 stages: Stage I corresponds to 
      sarcopenic patients with no other diabetes complication, and Stage II corresponds 
      to patients with some type of involvement. Within Stage II are three sublevels 
      (a, b and c). Stage IIa refers to individuals with sarcopenic diabetes and some 
      diabetes-specific impairment, IIb to sarcopenia with functional impairment, and 
      IIc to sarcopenia with diabetes complications and changes in function measured 
      using standard tests Conclusion: Diabetic sarcopenia has a significant impact on 
      function and quality of life in people with type 2 diabetes mellitus (T2DM), and 
      it is important to give it the same attention as all other traditionally 
      described complications of T2DM. This document aims to establish the foundation 
      for protocolising the screening and diagnosis of diabetic sarcopenia in a manner 
      that is simple and accessible for all levels of healthcare.
CI  - (c) 2024. The Author(s).
FAU - de Luis Roman, Daniel
AU  - de Luis Roman D
AD  - Center Investigacion of Endocrinology and Nutrition, University of Valladolid, 
      Valladolid, Spain. dadluis@yahoo.es.
FAU - Gomez, Juana Carretero
AU  - Gomez JC
AD  - Internal Medicine Department, University Hospital of Badajoz, Badajoz, Spain.
FAU - Garcia-Almeida, Jose Manuel
AU  - Garcia-Almeida JM
AD  - Clinical Management Unit of Endocrinology and Nutrition, Virgen de la Victoria 
      Clinical Hospital, Malaga, Spain.
FAU - Vallo, Fernando Garrachon
AU  - Vallo FG
AD  - Internal Medicine Department, Virgen de Macarena University Hospital, Seville, 
      Spain.
FAU - Rolo, German Guzman
AU  - Rolo GG
AD  - Medical Department, Abbott Laboratories, Madrid, Spain.
FAU - Gomez, Juan Jose Lopez
AU  - Gomez JJL
AD  - Endocrinology and Nutrition Department, University Clinical Hospital of 
      Valladolid, Valladolid, Spain.
FAU - Tarazona-Santabalbina, Francisco Jose
AU  - Tarazona-Santabalbina FJ
AD  - Geriatrics Department, University Hospital of la Ribera, Alzira, Valencia, Spain.
FAU - Sanz-Paris, Alejandro
AU  - Sanz-Paris A
AD  - Endocrinology Department, University Hospital Miguel Servet, Zaragoza, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240205
PL  - Germany
TA  - Rev Endocr Metab Disord
JT  - Reviews in endocrine & metabolic disorders
JID - 100940588
SB  - IM
OTO - NOTNLM
OT  - Diagnosis
OT  - HMB
OT  - Malnutrition
OT  - Muscle mass
OT  - Sarcopenia
OT  - Screening
OT  - Type 2 diabetes
EDAT- 2024/02/05 14:44
MHDA- 2024/02/05 14:44
CRDT- 2024/02/05 11:19
PHST- 2023/12/28 00:00 [accepted]
PHST- 2024/02/05 14:44 [medline]
PHST- 2024/02/05 14:44 [pubmed]
PHST- 2024/02/05 11:19 [entrez]
AID - 10.1007/s11154-023-09871-9 [pii]
AID - 10.1007/s11154-023-09871-9 [doi]
PST - aheadofprint
SO  - Rev Endocr Metab Disord. 2024 Feb 5. doi: 10.1007/s11154-023-09871-9.